These Analysts Increase Their Forecasts On Jazz Pharmaceuticals Following Q2 Results

Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) on Monday reported better-than-expected second-quarter sales results and raised its FY26 sales guidance above estimates. Jazz Pharmaceuticals reported quarterly earnings of $5.71 per share which missed the analyst consensus estimate of $6.18 per share. The company reported quarterly sales of $1.208 billion which beat the analyst consensus estimate of $1.115 billion. Jazz Pharmaceuticals raised its FY2026 sales guidance from $4.250 billion-$4.500 billion to $4.600 billion-$4.750 billion. “Our second quarter results highlight strong execution and momentum across the business, delivering 16% year-over-year total revenue growth and driving a considerable increase to our full-year revenue guidance,” said Renee Gala, president and chief executive officer of Jazz Pharmaceuticals. “We remain focused on long-term growth as we prepare t...